Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
04
2023
accepted:
18
07
2023
medline:
2
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Parkinson's disease has been identified as a risk factor for severe Coronavirus disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from COVID-19 in people with Parkinson's disease is specific to the disease itself or driven by other concomitant and known risk factors such as comorbidities, age, and frailty remains unclear. To investigate clinical profiles and outcomes of people with Parkinson's disease and atypical parkinsonian syndromes who tested positive for COVID-19 in the hospital setting in a multicentre UK-based study. A retrospective cohort study of Parkinson's disease patients with a positive SARS-CoV-2 test admitted to hospital between February 2020 and July 2021. An online survey was used to collect data from clinical care records, recording patient, Parkinson's disease and COVID-19 characteristics. Associations with time-to-mortality and severe outcomes were analysed using either the Cox proportional hazards model or logistic regression models, as appropriate. Data from 552 admissions were collected: 365 (66%) male; median (inter-quartile range) age 80 (74-85) years. The 34-day all-cause mortality rate was 38.4%; male sex, increased age and frailty, Parkinson's dementia syndrome, requirement for respiratory support and no vaccination were associated with increased mortality risk. Community-acquired COVID-19 and co-morbid chronic neurological disorder were associated with increased odds of requiring respiratory support. Hospital-acquired COVID-19 and delirium were associated with requiring an increase in care level post-discharge. This first, multicentre, UK-based study on people with Parkinson's disease or atypical parkinsonian syndromes, hospitalised with COVID-19, adds and expands previous findings on clinical profiles and outcomes in this population.
Sections du résumé
BACKGROUND
Parkinson's disease has been identified as a risk factor for severe Coronavirus disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from COVID-19 in people with Parkinson's disease is specific to the disease itself or driven by other concomitant and known risk factors such as comorbidities, age, and frailty remains unclear.
OBJECTIVE
To investigate clinical profiles and outcomes of people with Parkinson's disease and atypical parkinsonian syndromes who tested positive for COVID-19 in the hospital setting in a multicentre UK-based study.
METHODS
A retrospective cohort study of Parkinson's disease patients with a positive SARS-CoV-2 test admitted to hospital between February 2020 and July 2021. An online survey was used to collect data from clinical care records, recording patient, Parkinson's disease and COVID-19 characteristics. Associations with time-to-mortality and severe outcomes were analysed using either the Cox proportional hazards model or logistic regression models, as appropriate.
RESULTS
Data from 552 admissions were collected: 365 (66%) male; median (inter-quartile range) age 80 (74-85) years. The 34-day all-cause mortality rate was 38.4%; male sex, increased age and frailty, Parkinson's dementia syndrome, requirement for respiratory support and no vaccination were associated with increased mortality risk. Community-acquired COVID-19 and co-morbid chronic neurological disorder were associated with increased odds of requiring respiratory support. Hospital-acquired COVID-19 and delirium were associated with requiring an increase in care level post-discharge.
CONCLUSIONS
This first, multicentre, UK-based study on people with Parkinson's disease or atypical parkinsonian syndromes, hospitalised with COVID-19, adds and expands previous findings on clinical profiles and outcomes in this population.
Identifiants
pubmed: 37523365
doi: 10.1371/journal.pone.0285349
pii: PONE-D-23-09726
pmc: PMC10389727
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0285349Informations de copyright
Copyright: © 2023 Sorrell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
NPJ Parkinsons Dis. 2020 Aug 20;6:18
pubmed: 32885037
Mov Disord Clin Pract. 2021 Jul 30;8(7):1100-1106
pubmed: 34541022
Parkinsonism Relat Disord. 2020 Jun;75:126-127
pubmed: 32414669
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Mov Disord. 2020 Nov;35(11):1914-1915
pubmed: 32954522
Mov Disord Clin Pract. 2021 May 03;8(6):859-867
pubmed: 34226870
Am J Epidemiol. 2003 Jun 1;157(11):1015-22
pubmed: 12777365
PLoS One. 2022 Dec 22;17(12):e0278214
pubmed: 36548347
Clin Park Relat Disord. 2021 May 25;4:100095
pubmed: 34316672
Parkinsonism Relat Disord. 2020 Sep;78:134-137
pubmed: 32827969
NPJ Parkinsons Dis. 2021 Oct 11;7(1):92
pubmed: 34635668
Age Ageing. 2020 Oct 23;49(6):915-922
pubmed: 32778870
Mov Disord. 2020 Jun;35(6):905-908
pubmed: 32347572
BMC Geriatr. 2023 Jan 2;23(1):1
pubmed: 36593448
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Age Ageing. 2021 May 5;50(3):631-640
pubmed: 33951156
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Mov Disord. 2021 Jan;36(1):1-10
pubmed: 33196119
Rev Neurol (Paris). 2022 Jan-Feb;178(1-2):129-136
pubmed: 34556345
PeerJ. 2021 Apr 13;9:e11260
pubmed: 33954054
Brain. 2000 Nov;123 ( Pt 11):2297-305
pubmed: 11050029
J R Coll Physicians Edinb. 2018 Jun;48(2):103-107
pubmed: 29992197
Mov Disord. 2020 Aug;35(8):1295-1296
pubmed: 32583481
Ann Clin Transl Neurol. 2020 Nov;7(11):2221-2230
pubmed: 33016619
Anaesthesia. 2022 Jan;77 Suppl 1:49-58
pubmed: 35001383
Mov Disord. 2021 May;36(5):1049-1057
pubmed: 33942924
Mov Disord. 2005 Oct;20(10):1255-63
pubmed: 16041803
PLoS One. 2021 Oct 5;16(10):e0258095
pubmed: 34610034
BMJ. 2020 Oct 20;371:m3731
pubmed: 33082154
J Neurol. 2021 Aug;268(8):2666-2670
pubmed: 33098468
Int Rev Neurobiol. 2022;165:35-62
pubmed: 36208906
Parkinsonism Relat Disord. 2008;14(4):334-7
pubmed: 17988926
J Neurol. 2022 Mar;269(3):1107-1113
pubmed: 34482434
J Parkinsons Dis. 2022;12(6):1833-1840
pubmed: 35634853
Thorax. 2022 Nov;77(11):1113-1120
pubmed: 34819384
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
J Neural Transm (Vienna). 2021 Jan;128(1):37-48
pubmed: 33392827
Ir J Med Sci. 2022 Feb;191(1):21-26
pubmed: 33566314
Neurology. 2014 Oct 14;83(16):1396-402
pubmed: 25217056
Mov Disord. 2010 Apr 30;25(6):710-6
pubmed: 20213822
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Nat Rev Dis Primers. 2021 Jul 1;7(1):47
pubmed: 34210995
J Comp Eff Res. 2022 Jun;11(9):689-698
pubmed: 35510532
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466
Mov Disord. 2020 Jul;35(7):1095-1096
pubmed: 32395849